ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 128

Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

Emily Smitherman1, Rouba Chahine 1, Timothy Beukelman 1, Andrea Knight 2, AKM Fazlur Rahman 1, Mary Beth Son 3, Jeffrey R Curtis 4 and Aimee Hersh 5 for the CARRA investigators, 1University of Alabama at Birmingham, Birmingham, 2SickKids Research Institute, Toronto, Canada, 3Boston Children's Hospital, Boston, Massachusetts, 4University of Alabama at Birmingham, Hoover, 5University of Utah Primary Children's Hospital, Salt Lake City

Meeting: Pediatric Rheumatology Symposium 2020

Keywords: Disease Activity, health disparities, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of longitudinal disease activity to mitigate this risk. Our objective was to determine patient-level demographic and clinical predictors for follow-up moderate/high disease activity scores in the Childhood Arthritis and Rheumatic Disease Research Alliance (CARRA) Registry. We hypothesized that minority race/ethnicity would be associated with moderate/high disease activity.

Methods: We performed a retrospective analysis of prospectively collected data from March 2017 to June 2019 in the CARRA Registry. Data was collected every 6 months, and patients with at least two study visits were included. The primary outcome was Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at most recent follow-up visit, dichotomized into ≤ 4 (low disease activity) or > 4 (moderate/high disease activity). Predictor variables included sex, race/ethnicity, household income, parental education level, insurance status, age at diagnosis, cumulative number of ACR and SLICC classification criteria, ever presence of lupus nephritis and neuropsychiatric lupus, time between reported symptom onset and diagnosis, SLEDAI-2K at enrollment, and physician global assessment (PGA) of disease activity (0-10) at enrollment. Time from diagnosis to enrollment and time from diagnosis to most recent visit were also collected. Multivariable logistic regression was used to determine predictors for moderate/high disease activity at most recent follow-up visit using SAS v9.4.

Results: We identified 324 cSLE patients with at least two study visits in the registry (Table 1). The cohort was 85% female, 28% Black, 25% White, and 22% Hispanic with a mean (SD) age at diagnosis of 13.8 (2.9) years. The mean (SD) time from diagnosis to most recent visit was 26.5 (23) months. At the most recent visit, 27% of patients had moderate/high disease activity. Lupus nephritis had been present in 43% and neuropsychiatric lupus in 29%. Statistically significant differences between the low and moderate/high disease activity groups were noted in the number of cumulative ACR and SLICC criteria, SLEDAI-2K at enrollment, and PGA at enrollment (Table 1). In a multivariable logistic regression model, higher number of SLICC criteria (OR=1.3, 95% CI=1.1–1.6, p< 0.001) and non-private insurance status (OR=2.2, 95% CI=1.1–4.4, p=0.03) were independently associated with moderate/high disease activity (Table 2).

Conclusion: This study provides an initial analysis of predictors of cSLE disease activity scores from the longitudinal CARRA Registry. There was a substantial proportion of patients with moderate/high disease activity at their most recent visit. Race/ethnicity was not a significant predictor of SLEDAI-2K but non-private insurance status was significant, suggesting that additional measures of socioeconomic status should be explored in further analyses. In summary, continued investigation is needed to better understand modifiers of disease activity in order to identify targets for intervention and improved outcomes.


Disclosure: E. Smitherman, None; R. Chahine, None; T. Beukelman, UCB, 1, Novartis, 1; A. Knight, None; A. Rahman, None; M. Son, None; J. Curtis, AbbVie, 1, Amgen, 1, Bristol-Myers Squibb, 1, Corrona, 1, Lilly, 1, Janssen, 1, Myriad, 1, Pfizer, 1, Regeneron, 1, Roche, 1, UCB, 1; A. Hersh, None.

To cite this abstract in AMA style:

Smitherman E, Chahine R, Beukelman T, Knight A, Rahman A, Son M, Curtis J, Hersh A. Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/predictors-of-moderate-high-disease-activity-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to Pediatric Rheumatology Symposium 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-moderate-high-disease-activity-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology